GE9:F:F-Genmab A/S (EUR)

COMMON STOCK | |

Last Closing

USD 234.4

Change

+1.70 (+0.73)%

Market Cap

USD 15.01B

Volume

3.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
NNND:F Tencent Holdings Ltd

+0.67 (+1.23%)

USD 492.09B
MATA:F Panasonic Corporation

N/A

USD 20.38B
1CK:F CK Asset Holdings Limited

+0.01 (+0.18%)

USD 14.81B
0PY:F Paycom Soft

+1.65 (+1.10%)

USD 8.79B
2U4:F HICL Infrastructure PLC

-0.02 (-1.30%)

USD 2.89B
28MA:F CIELO SA SPONS. ADR 1

N/A

USD 2.57B
CLN:F The City of London Investment ..

N/A

USD 2.10B
R7I:F RENEWABLES INFRASTRUCTURE

-0.08 (-6.44%)

USD 1.77B
JR0:F Just Group plc

+0.03 (+1.85%)

USD 1.74B
CE2:F CropEnergies AG

N/A

USD 1.00B

ETFs Containing GE9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.44% N/A N/A 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.44% N/A N/A 21% F
Trailing 12 Months  
Capital Gain -32.31% N/A N/A 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.31% N/A N/A 20% F
Trailing 5 Years  
Capital Gain 45.45% N/A N/A 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.45% N/A N/A 56% F
Average Annual (5 Year Horizon)  
Capital Gain 13.33% N/A N/A 78% C+
Dividend Return 13.33% N/A N/A 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.51% N/A N/A 38% F
Risk Adjusted Return 42.30% N/A N/A 66% D+
Market Capitalization 15.01B N/A N/A 90% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike